This company listing is no longer active
Valeo Pharma Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Al Moghaddam
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.6yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
CEO
Al Moghaddam (57 yo)
less than a year
Tenure
Mr. Al Moghaddam, B. Com. CMA had been a Director at Valeo Pharma Inc. since March 21, 2024 until June 2024 and served as its Chief Development Officer since June 2024 until August 2024 and serves as its C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP & Chief Commercial Officer | 2.3yrs | CA$388.21k | 0.020% € 96.9 | |
| Chief Executive Officer | less than a year | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Director of Communications & Investor Relations | no data | no data | 0.26% € 1.3k | |
| VP of Legal Affairs & Corporate Secretary | no data | no data | 0% € 0 | |
| Head of Ophthalmology Business Unit | 2.3yrs | no data | no data |
1.6yrs
Average Tenure
Experienced Management: VP2's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | less than a year | no data | 0.18% € 875.0 | |
| Chairman of the Advisory Board & Director | 15.8yrs | no data | 16.44% € 81.1k | |
| Chairman | 21.7yrs | CA$466.29k | 0.18% € 903.7 | |
| Independent Non-Executive Director | 2.6yrs | no data | 2.36% € 11.7k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
1.8yrs
Average Tenure
65yo
Average Age
Experienced Board: VP2's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/21 12:41 |
| End of Day Share Price | 2024/10/02 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2023/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Valeo Pharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neil Linsdell | iA Capital Markets |
| Chelsea Stellick | iA Capital Markets |
| Scott McAuley | Paradigm Capital, Inc. |